scholarly journals Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials

Liver Cancer ◽  
2016 ◽  
Vol 5 (3) ◽  
pp. 162-174 ◽  
Author(s):  
Hee Chul Park ◽  
Jeong Il Yu ◽  
Jason Chia-Hsien Cheng ◽  
Zhao Chong Zeng ◽  
Ji Hong Hong ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Trials ◽  
Liver Cancer ◽  
Current Practice ◽  
Primary Liver Cancer ◽  
Asia Pacific ◽  
Expert Meeting

scholarly journals Novel Imaging Diagnosis for Hepatocellular Carcinoma: Consensus from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014)

Liver Cancer ◽  
2015 ◽  
Vol 4 (4) ◽  
pp. 215-227 ◽  
Author(s):  
Bang-Bin Chen ◽  
Takamichi Murakami ◽  
Tiffany Ting-Fang Shih ◽  
Michiie Sakamoto ◽  
Osamu Matsui ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Cancer ◽  
Primary Liver Cancer ◽  
Asia Pacific ◽  
Imaging Diagnosis ◽  
Expert Meeting

scholarly journals Consensus Development from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014)

Liver Cancer ◽  
2015 ◽  
Vol 4 (2) ◽  
pp. 96-105 ◽  
Author(s):  
Chiun Hsu ◽  
Bang-Bin Chen ◽  
Chien-Hung Chen ◽  
Ming-Chih Ho ◽  
Jason Chia-Hsien Cheng ◽  
...  
Keyword(s):  
Liver Cancer ◽  
Primary Liver Cancer ◽  
Asia Pacific ◽  
Consensus Development ◽  
Expert Meeting

scholarly journals The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials

2021 ◽  
Vol 11 ◽  
Author(s):  
Muhammet Ozer ◽  
Andrew George ◽  
Suleyman Yasin Goksu ◽  
Thomas J. George ◽  
Ilyas Sahin
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Trials ◽  
Cell Death ◽  
Liver Cancer ◽  
Programmed Cell Death ◽  
Immune Checkpoint ◽  
Primary Liver Cancer ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Line Treatment

The prevalence of primary liver cancer is rapidly rising all around the world. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Unfortunately, the traditional treatment methods to cure HCC showed poor efficacy in patients who are not candidates for liver transplantation. Until recently, tyrosine kinase inhibitors (TKIs) were the front-line treatment for unresectable liver cancer. However, rapidly emerging new data has drastically changed the landscape of HCC treatment. The combination treatment of atezolizumab plus bevacizumab (immunotherapy plus anti-VEGF) was shown to provide superior outcomes and has become the new standard first-line treatment for unresectable or metastatic HCC. Currently, ongoing clinical trials with immune checkpoint blockade (ICB) have focused on assessing the benefit of antibodies against programmed cell death 1 (PD-1), programmed cell death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte- associated antigen 4 (CTLA-4) as monotherapies or combination therapies in patients with HCC. In this review, we briefly discuss the mechanisms underlying various novel immune checkpoint blockade therapies and combination modalities along with recent/ongoing clinical trials which may generate innovative new treatment approaches with potential new FDA approvals for HCC treatment in the near future.

Sign in / Sign up

Export Citation Format

Share Document